FORM D



UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

OMB APPROVAL

OMB Number: Expires: 3235-0076

Expires: May 31, 2005
Estimated average burden

hours per form1

NOTICE OF SALE OF SECURITIES HOR PURSUANT TO REGULATION D. FINA

SECTION 4(6), AND/OR

UNIFORM LIMITED OFFERING EXEMPTION

SEC USE ONLY					
Prefix	Serial				
DATE RI	ECEIVED				

Name of Offering (Scheck if this is an amendment and name has changed, and indicate change.)

Convertible Promissory Note Financing

Conventioned Tollingsory Polic Timaler	···6							
Filing Under (Check box(es) that apply):	Rule 504	Rule 505	⊠Ru	le 506	Section 4(6)	ULOE		
Type of Filing:	□Ne	w Filing		⊠Amendment				
	A. BASIC ID	ENTIFICATION	DATA					
1. Enter the information requested about the is	ssuer							
Name of Issuer (check if this is an amendme Imaging Therapeutics, Inc.	nt and name has chan	ged, and indicate c	hange.)					
Address of Executive Offices (Number and Street, City, State, Zip Code) Suite 240; 1720 South Amphlett Boulevard.; San Mateo, CA 94402 Telephone Number (Including Area Code) (650) 286-4151								
Address of Principal Business Operations same as above	(Number and Street, City, State, Zip Code) Telephone Number (Including Area C same							
Brief Description of Business Medical Device								
Type of Business Organization								
⊠ corporation	limited partners	hip, already formed	1	l	other (please specif	y)		
business trust	limited partners	hip, to be formed	····					
		<u>Month</u>	<u>Year</u>					
Actual or Estimated Date of Incorporation or O	rganization:	3	00	1	Actual	☐ Estimated		
Jurisdiction of Incorporation or Organization:	(Enter two-letter U CN for Canada, FN			for State:	CA			

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C 77d(6).

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

<u>Copies Required</u>: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

A. BASIC IDENTIFICATION DATA

- 2. Enter the information requested for the following:
 - Each promoter of the issuer, if the issuer has been organized within the past five years;
 - Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;

the issuer;			
 Each executive officer a 	and director of corporate issuers and	of corporate general and managing partners of p	artnership issuers; and
 Each general and management 	ging partner of partnership issuers.		
Check Box(es)	Promoter	⊠Beneficial Owner	☐Executive Officer
that Apply:	⊠Director	General and/or Managing Partner	
Full Name (Last name first, if in	ndividual)		
Philipp Lang			
	(Number and Street, City, State, Zi		
c/o Imaging Therapeutics, Inc.,	Suite 240; 1720 South Amphlett Bo	ulevard; San Mateo, CA 94402	
Check Box(es)	Promoter	⊠Beneficial Owner	Executive Officer
that Apply:	Director	General and/or Managing Partner	
Full Name (Last name first, if it			
CDIB Biotech U.S.A. Investme	nt, Co., Ltd.		
	(Number and Street, City, State, Zip	Code)	
125 Nanking East Road; Section	n 5, Taipei 105; Taiwan, R.O.C.		
Check Box(es)	Promoter	⊠Beneficial Owner	Executive Officer
that Apply:	Director	General and/or Managing Partner	
Full Name (Last name first, if it	ndividual)	· · · · · · · · · · · · · · · · · · ·	
Daniel Steines			
Business or Residence Address	(Number and Street, City, State, Zip	p Code)	
c/o Imaging Therapeutics, Inc.,	Suite 240; 1720 South Amphlett Bo	ulevard; San Mateo, CA 94402	
Check Box(es)	Promoter	⊠Beneficial Owner	Executive Officer
that Apply:	Director	General and/or Managing Partner	_
Full Name (Last name first, if it	ndividual)		
Eugene Alexander			
Business or Residence Address	(Number and Street, City, State, Zip	Code)	
	Suite 240; 1720 South Amphlett Bo		
Check Box(es)	Promoter	⊠Beneficial Owner	Executive Officer
that Apply:	Director	General and/or Managing Partner	
Full Name (Last name first, if ir	ndividual)		
Thomas Andriacchi			
Business or Residence Address	(Number and Street, City, State, Zip	Code)	
	Suite 240; 1720 South Amphlett Bo		
Check Box(es)	Promoter	⊠Beneficial Owner	Executive Officer
that Apply:	Director	General and/or Managing Partner	
Full Name (Last name first, if in	ndividual)		
Thorner Ventures			
Business or Residence Address	(Number and Street, City, State, Zip	(Code)	
21 Acorn Way, Kentfield, CA 9			
Check Box(es)	Promoter	⊠Beneficial Owner	Executive Officer
that Apply:	Director	General and/or Managing Partner	
Full Name (Last name first, if it			
Der Yang Biotechnology Ventu	ire Capital, Ltd.		
Business or Residence Address	(Number and Street, City, State, Zip	Code)	
4FI, No. 552, Jungshiau E Rd.,		,	
Check Box(es)	Promoter	Beneficial Owner	Executive Officer
that Apply:	Director	General and/or Managing Partner	LILACCUAVE OTHER
Full Name (Last name first, if in		Light and of managing Latines	
Aaron Berez			
Business or Residence Address	(Number and Street, City, State, Zip	(Code)	
	Suite 240; 1720 South Amphlett Bo		

Check Box(es)	Promoter	Beneficial Owner	☐Executive Officer
that Apply:	Director	General and/or Managing Partner	
Full Name (Last name first, if i	ndividual)		
Anselm Leung			
Business or Residence Address	(Number and Street, City, State, Zip	Code)	
c/o Imaging Therapeutics, Inc.,	ulevard; San Mateo, CA 94402		
Check Box(es)	Promoter	Beneficial Owner	
that Apply:	Director	General and/or Managing Partner	
Full Name (Last name first, if i	ndividual)		
Barry Linder			
Business or Residence Address	(Number and Street, City, State, Zip	Code)	
c/o Imaging Therapeutics, Inc.,	Suite 240; 1720 South Amphlett Bo	ulevard; San Mateo, CA 94402	

				RI	NFORMAT	TION AROL	UT OFFFR	ING			·		
				D, 1	NFORWIA I	TION ADO	OI OFFER	1110					
1. H	Has the issuer	sold, or does	the issuer in		to non-accre o in Append			-		Yes 🗌	No 🛛		
2. \	2. What is the minimum investment that will be accepted from any individual?												
3. Does the offering permit joint ownership of a single unit?											No 🗌		
r	4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.												
Full	Name (Last na	me first, if in	idividual)										
Busi	ness or Reside	nce Address	(Number and	1 Street, City	y, State, Zip	Code)							
Nam	e of Associate	d Broker or I	Paglar										
INAIII	ie of Associate	d blokel of 1	Jealei										
State	s in Which Pe	rson Listed F	Ias Solicited	or Intends t	o Solicit Pur	rchasers		-	 				
•	ck "All States			•									
[AL]		[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]	
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]	
[MT [RI]	[NE] [SC]	[NV] [SD]	[NH] [TN]	[NJ] [TX]	[NM] [UT]	[NY] [VT]	[NC] [VA]	[ND] [VA]	[OH] [WV]	(OK) [WI]	[OR] [WY]	[PA] [PR]	
<u> </u>	Name (Last na			(17)	[01]	[* x]	[YA]	[vaj	[** *]	[[[]]	[11]	(I K)	
1 un	Ivanic (Last in	ine mst, n n	idividuai)										
Busi	ness or Reside	nce Address	(Number and	d Street, Cit	y, State, Zip	Code)							
Nam	e of Associate	d Broker or I	Dealer			-					<u>.</u>		
State	es in Which Pe	erson Listed F	las Solicited	or Intends t	o Solicit Pur	rchasers							
	ck "All States									All States			
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	(FL)	[GA]	(HI)	[ID]	
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]	
[MT] [NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]	
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[VA]	[WV]	[WI]	[WY]	[PR]	
Full	Name (Last na	ame first, if in	ndividual)										
Busi	ness or Reside	ence Address	(Number and	d Street, Cit	y, State, Zip	Code)			<u></u>				
Nam	ne of Associate	d Broker or I	Dealer						-				
State	es in Which Pe	erson Listed F	las Solicited	or Intends t	o Solicit Pui	rchasers							
•	eck "All States	" or check in	dividual Stat							All States			
[AL]		[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]	
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]	
[MT		[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]	
[RI]	[SC]	[SD]	[TN]	[TX]	(UT)	[VT]	[VA]	[VA]	[WV]	[WI]	[WY]	[PR]	

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS 1. Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \(\square\) and indicate in the columns below the amounts of the securities offering for exchange and already exchanged. Aggregate Offering Price Amount Already Sold Type of Security Debt..... 2,500,000\$ 2,397,900 Equity..... Common Common Preferred Convertible Securities (including warrants)..... Partnership Interests..... Other (Specify ______)..... Total \$ 2,500,000 2,397,900 Answer also in Appendix, Column 3, if filing under ULOE. 2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero." Number Investors Aggregate Dollar Amount of Purchases \$ 2,397,900 Accredited Investors Non-accredited Investors Total (for filings under Rule 504 only)..... Answer also in Appendix, Column 4, if filing under ULOE. 3. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1. Type of Offering Type of Security Dollar Amount Sold Rule 505..... Regulation A Rule 504..... Total 4. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate. Transfer Agent's Fees Printing and Engraving Costs Legal Fees 25,000 Accounting Fees..... Engineering Fees..... Sales Commissions (specify finders' fees separately) Other Expenses (Identify) Blue Sky fees 710 Total..... 25,710 b. Enter the difference between the aggregate offering price given in response to \$ 2,372,190 Part C - Question 1 and total expenses furnished in response to Part C -Question 4.a. This difference is the "adjusted gross proceeds to the issuer"

C. OFFERING PRICE, NUMBER OF INVESTO	ORS, EXPENSES AND USE OF PI	ROCEEDS
5. Indicate below the amount of the adjusted gross proceeds to the issuer use proposed to be used for each of the purposes shown. If the amount for ar purpose is not known, furnish an estimate and check the box to the left of estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above.	ry Ethe	
	Payment to Officers	
	Directors, & Affiliate	
Salaries and fees	-	□ \$
Purchase of real estate	<u> </u>	□ \$ □ \$
Purchase, rental or leasing and installation of machinery and equipment		□ \$
Construction or leasing of plant buildings and facilities		□ •
offering that may be used in exchange for the assets or securities of another is		
pursuant to a merger)		
Repayment of indebtedness	\$	 \$
Working capital	\$	⋈ \$ <u>2,372,190</u>
Other (specify):		
		_
Column Totals		\$2,372,190
Total Payments Listed (column totals added)		\$_2,372,190
D. FEDERAL S	IGNATURE	
		ed under Rule 505, the following
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur	uthorized person. If this notice is fil ities and Exchange Commission, upo	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to	uthorized person. If this notice is fil ities and Exchange Commission, upo paragraph (b)(2) of Rule 502.	on written request of its staff, the
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upo	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc.	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502.	on written request of its staff, the
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502.	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type)	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type)	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type)	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type)	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type)	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type)	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type)	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type)	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type)	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type)	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type)	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type)	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type)	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type)	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type)	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type) George Colindres	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type) Assistant Secretary	Date
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Imaging Therapeutics, Inc. Name of Signer (Print or Type)	uthorized person. If this notice is fil ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type) Assistant Secretary	Date

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

	E. STATE SIGNATURE
1. Is any party described in 17-CFR 230.252(c), (d), (e) or (provisions of such rule?	
See App	pendix, Column 5, for state response.
2. The undersigned issuer hereby undertakes to furnish to the CFR 239.500) at such times as required by state law.	ne state administrator of any state in which the notice is filed, a notice on Form D (17
3. The undersigned issuer hereby undertakes to furnish to an offerees.	ny state administrators, upon written request, information furnished by the issuer to
	iar with the conditions that must be satisfied to be entitled to the Uniform limited office is filed and understands that the issuer claiming the availability of this exemption been satisfied.
The issuer has read this notification and knows the contents to duly authorized person.	to be true and has duly caused this notice to be signed on its behalf by the undersigned
Issuer (Print or Type) Imaging Therapeutics, Inc.	Signature Date February 14, 2004
Name of Signer (Print or Type) George Colindres	Title of Signer (Print or Type) Assistant Secretary

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

. ` APPENDIX										
1		2	3		4	4		:	5	
		o non-accredited te (Part B-Item 1)	and aggregate offering price edited offered in State Type of investor and amount purchased in State				under Sta (if yes explant waiver	Disqualification under State ULOE (if yes, attach explanation of waiver granted (Part E-Item 1)		
			Convertible Promissory Note (Equity Securities) and Warrants	Number of Non-Accredited Accredited						
State	Yes	No	(Common Stock)	Investors	Amount	Investors	Amount	Yes	No	
AL										
AK										
AZ										
AR										
CA		Х	\$480,000	8	\$480,000	0	\$0		X	
СО										
СТ		<u> </u>								
DE										
DC										
FL							· · · · · · · · · · · · · · · · · · ·			
GA		·								
ні		<u> </u>								
ID										
1L										
IN										
IA										
KS										
KY										
LA										
ME										
MD										
MA							-			
MI										

APPENDIX									
MN									
MS									
МО			1						
MT									
NE									
NV									
NH									
NJ									
NM									
NY									
NC									
ND			!						
ОН									
OK									
OR									
PA									
RI									
SC									
SD									
TN									
TX									
UT		X	\$50,000	2	\$50,000	0	\$0		Х
VT									
VA									
WA		Х	\$60,000	2	\$60,000	0	\$0		Х
WV									
WI		Х	\$80,000	1	\$80,000	0	\$0		Х
WY									
PR						<u> </u>			